Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 3/20 | 0.35 |
| ▸ | PLAU | P00749 | 3/20 | 0.35 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.35 |
| ▸ | ELANE | P08246 | 3/20 | 0.35 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19010740 | 0.87 | HTT (0.36) | HTTALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL17796442 | 0.84 | HTT (0.36) | HTTALDH1A1GAAMEN1KMT2A | |
| SCHEMBL29625026 | 0.83 | MEN1 (0.37) | HTTALDH1A1GAAMEN1KMT2A | |
| SCHEMBL21960887 | 0.83 | BRD4 (0.43) | HTTALDH1A1GAAMEN1KMT2A | |
| SCHEMBL19027056 | 0.80 | MITF (0.40) | HTTALDH1A1NPC1ELANEHPGD | |
| SCHEMBL2119388 | 0.78 | KDM4E (0.50) | HTTALDH1A1GAAMEN1KMT2A | |
| SCHEMBL19010745 | 0.78 | L3MBTL1 (0.49) | ALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL21961348 | 0.78 | BRD4 (0.46) | HTTALDH1A1LMNA | |
| SCHEMBL2372926 | 0.77 | HTT (0.45) | HTTALDH1A1GAAMEN1KMT2A | |
| SCHEMBL15767909 | 0.77 | HTT (0.36) | HTTALDH1A1MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102791714-B | N-(imidazopyrimidin-7-yl)-heteroarylamide derivatives and their use as PDE10A inhibitors | HOFFMANN LA ROCHE | 2015-03-25 | — | — | CN | claimed |
| EP-2552918-B1 | N-(IMIDAZOPYRIMIDIN-7-YL)-HETEROARYLAMIDE DERIVATIVES AND THEIR USE AS PDE10A INHIBITORS | HOFFMANN LA ROCHE (CH) | 2014-06-11 | — | — | EP | claimed |
| US-8410117-B2 | Imidazopyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-04-02 | — | — | US | claimed |
| EP-2552918-A1 | N-(IMIDAZOPYRIMIDIN-7-YL)-HETEROARYLAMIDE DERIVATIVES AND THEIR USE AS PDE10A INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2013-02-06 | — | — | EP | claimed |
| CN-102791714-A | N-(imidazopyrimidin-7-yl)-heteroarylamide derivatives and their use as PDE10A inhibitors | HOFFMANN LA ROCHE | 2012-11-21 | — | — | CN | claimed |
| CN-109641882-B | Heteroaromatic derivatives as NIK inhibitors | 杨森制药有限公司 | 2022-10-28 | — | — | CN | disclosed |
| US-11136311-B2 | Heteroaromatic derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-05 | — | — | US | disclosed |
| EP-3478675-B1 | HETEROAROMATIC DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-22 | — | — | EP | disclosed |
| EP-3478675-A1 | HETEROAROMATIC DERIVATIVES AS NIK INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2019-05-08 | — | — | EP | disclosed |
| WO-2018002217-A1 | HETEROAROMATIC DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-01-04 | — | — | WO | disclosed |
| CN-102791714-B | N-(imidazopyrimidin-7-yl)-heteroarylamide derivatives and their use as PDE10A inhibitors | HOFFMANN LA ROCHE | 2015-03-25 | — | — | CN | disclosed |
| EP-2552918-B1 | N-(IMIDAZOPYRIMIDIN-7-YL)-HETEROARYLAMIDE DERIVATIVES AND THEIR USE AS PDE10A INHIBITORS | HOFFMANN LA ROCHE (CH) | 2014-06-11 | — | — | EP | disclosed |
| US-8410117-B2 | Imidazopyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-04-02 | — | — | US | disclosed |
| EP-2552918-A1 | N-(IMIDAZOPYRIMIDIN-7-YL)-HETEROARYLAMIDE DERIVATIVES AND THEIR USE AS PDE10A INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2013-02-06 | — | — | EP | disclosed |
| CN-102791714-A | N-(imidazopyrimidin-7-yl)-heteroarylamide derivatives and their use as PDE10A inhibitors | HOFFMANN LA ROCHE | 2012-11-21 | — | — | CN | disclosed |
| US-20110237564-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2011-09-29 | — | — | US | disclosed |
| WO-2011117264-A1 | N-(IMIDAZOPYRIMIDIN-7-YL)-HETEROARYLAMIDE DERIVATIVES AND THEIR USE AS PDE10A INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237564-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | PDE5A, PDE3B, PDE3A | HTT 4569/4885ALDH1A1 105/4885GAA 984/4885 |
| US-11136311-B2 | Heteroaromatic derivatives as NIK inhibitors | NFKBIA, IKBKG, IKBKE | HTT 2659/4885ALDH1A1 3872/4885GAA 1383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.